Fellowship, University of Washington, Infectious Diseases, 1977.
EIS Officer, Centers for Disease Control and Prevention (CDC), Internal Medicine Training, 1975.
Residency, University of Michigan, Medical Center Hospitals, Internal Medicine, 1973.
M.D., University of Michigan, 1971.
The herpes virus research program at the University of Washington involves studies in HSV, CMV, HHV-6 and HHV-8. The genital HSV program has been the most longstanding, having had continuous NIH funding since 1978. This program involves clinical investigations of HSV reactivation and transmission, laboratory based studies on the cellular immunology of HSV, and characterization of HSV-HIV interactions. In the last few years, the laboratory has focused on developing an HSV vaccine by defining the T-cell responses to HSV, especially cytotoxic T-cell responses as a means of developing CTL-based vaccines for immunotherapy or prophylaxis of genital HSV. The laboratory based programs involve collaborations with Drs. Jia Zhu, Research Assistant Professor; David Koelle, Professor of Medicine; Keith Jerome, Professor of Laboratory Medicine, University of Washington and now Head of the Diagnostic Virology Division; and Christine Posavad, Senior Scientist at the Hutchinson Center. The Clinical Research Program in genital herpes is directed by Dr. Anna Wald, Professor of Medicine, University of Washington and Dr. Christine Johnston, Assistant Professor of Medicine, University of Washington. Dr. Wald is medical director of the Viral Disease Clinic, a specialty clinic dedicated to a wide range of clinical studies on HSV infection, including resolution frequency, vaccine efficacy and technology development.
The program in HHV-8 infection encompasses studies of the transmission of HHV-8 and the mechanism by which HHV-8 induces Kaposi’s sarcoma. This work is done with Dr. Corey Casper, Associate Member at the Hutchinson Center. Clinical trials for HHV-8 prevention are conducted in the newly formed Uganda Program on Cancer and Infectious Diseases under the direction of Dr. Orem Jackson of the Uganda Cancer Institute and Dr. Corey Casper and Dr. Warren Phipps at the Hutchinson Center.
The Vaccine and Infectious Disease Division (VIDD) of the Hutchinson Center is home to many researchers studying prevention of CMV and HHV-6 infections in the immunocompromised host and the role these infections play in the morbidity of HSCT. Dr. Michael Boeckh, Professor of Medicine heads research on CMV infection in collaboration with Dr. Steven Pergam, Associate Professor in Medicine.
The HIV research program directed by Dr. Corey includes both laboratory and clinical investigation. Dr. Corey is the co-PI of the NIAID supported HIV Vaccine Trials Network (HVTN), a global network of clinical trial sites and laboratories dedicated to phase I-III trials of candidate HIV vaccines and other preventative and treatment options. Other faculty members involved in the effort are Drs. Juliana McElrath, Peter Gilbert and Jim Kublin. Training opportunities for postdoctoral fellows interested in learning vaccine biology and clinical trial research are available within the network.
Dr. Corey is a member of numerous committees and editorial boards in areas of infectious diseases, HIV infection, and HIV vaccines. He is a member of the National Cancer Institute Board of Scientific Counselors, Basic Sciences.
American Epidemiological Society
American Federation for Clinical Research
American Society of Clinical Investigation
Association of American Physicians
Infectious Diseases Society of America
Institute of Medicine
Western Association of Physicians
Honors and Awards
2012, Recipient, 2012 Cubist-ICAAC Award, American Society for Microbiology
2012, Elected, Member, American Academy of Arts and Sciences
2011, Lifelong AIDS Alliance "Ned Behnke Leadership Award"
2008, Elected, National Academy of Sciences, Institute of Medicine, National Academy of Sciences
2007-2010, Co-Director, Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division
2007-2010, Senior Vice President, Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division
1996-2010, Head, Fred Hutchinson Cancer Research Center, Clinical Research Division, Infectious Disease Sciences
1978-2010, Head, Virology Division, Department of Laboratory Medicine, School of Medicine, University of Washington
Helicase-primase inhibitor pritelivir for HSV-2 infection.. The New England journal of medicine. 370(3):201-10.. 2014.
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine.. 2013.
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection.. Nature. 497(7450):494-7.. 2013.
Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2013.
Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.. Nature medicine. 19(3):280-8.. 2013.
High-Dose Valacyclovir Decreases Plasma HIV-1 RNA More Than Standard-Dose Acyclovir in Persons Coinfected with HIV-1 and HSV-2: A Randomized Crossover Trial.. Journal of acquired immune deficiency syndromes (1999). 63(2):201-8.. 2013.
Self Collection of Foam Nasal Swabs for Respiratory Virus Detection by PCR among Immunocompetent Subjects and Hematopoietic Cell Transplant Recipients.. Journal of clinical microbiology. 51(1):324-327.. 2013.
Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.. 2013.
Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.. Antimicrobial agents and chemotherapy. 57(12):5820-9.. 2013.
Daily Acyclovir to Decrease Herpes Simplex Virus Type 2 (HSV-2) Transmission from HSV-2/HIV-1 Coinfected Persons: A Randomized Controlled Trial.. The Journal of infectious diseases.. 2013.
HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.. Proceedings of the National Academy of Sciences of the United States of America. 110(33):13492-7.. 2013.
The need and challenges for development of an Epstein-Barr virus vaccine.. Vaccine. 31 Suppl 2:B194-6.. 2013.
Changes in the Soluble Mucosal Immune Environment during Genital Herpes Outbreaks.. Journal of acquired immune deficiency syndromes (1999). 61(2):194-202.. 2012.
An Effector Phenotype of CD8+ T Cells at the Junction Epithelium during Clinical Quiescence of Herpes Simplex Virus 2 Infection.. Journal of virology. 86(19):10587-96.. 2012.
WU and KI Polyomaviruses in Respiratory Samples from Allogeneic Hematopoietic Cell Transplant Recipients.. Emerging infectious diseases. 18(10):1580-8.. 2012.
Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(11):1687-99.. 2012.
HHV-6 Reactivation and Associated Sequelae after Hematopoietic Cell Transplant.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(11):1700-1708.. 2012.
Acyclovir achieves lower concentration in African HIV-seronegative, HSV-2 seropositive women compared to non-African populations.. Antimicrobial agents and chemotherapy. 56(5):2777-9.. 2012.
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.. Clinical investigation. 2(3):245-254.. 2012.